Birchview Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Birchview Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.15M	Hold	57,000	–	–	0.65%	38
2025 Q4	$921K	Sell	57,000 -10,000	-15%	-$132K	0.54%	42
2025 Q3	$816K	Hold	67,000	–	–	0.62%	41
2025 Q2	$757K	Sell	67,000 -2	-0%	-$24	0.75%	30
2025 Q1	$773K	Buy	67,002 +2	+0%	+$20	0.67%	25
2024 Q4	$567K	Sell	67,000 -15,000	-18%	-$155K	0.46%	29
2024 Q3	$950K	Buy	82,000 +36,000	+78%	+$453K	0.82%	24
2024 Q2	$542K	Hold	46,000	–	–	0.5%	29
2024 Q1	$546K	Buy	46,000 +6,000	+15%	+$80K	0.44%	34
2023 Q4	$490K	Hold	40,000	–	–	0.38%	34
2023 Q3	$385K	Hold	40,000	–	–	0.33%	35
2023 Q2	$360K	Hold	40,000	–	–	0.27%	42
2023 Q1	$314K	Hold	40,000	–	–	0.25%	42
2022 Q4	$270K	Hold	40,000	–	–	0.19%	44
2022 Q3	$580K	Hold	40,000	–	–	0.41%	36
2022 Q2	$394K	Hold	40,000	–	–	0.29%	43
2022 Q1	$590K	Hold	40,000	–	–	0.42%	38
2021 Q4	$529K	Hold	40,000	–	–	0.34%	42
2021 Q3	$698K	Hold	40,000	–	–	0.48%	34
2021 Q2	$958K	Hold	40,000	–	–	0.57%	33
2021 Q1	$1.03M	Buy	40,000 +10,000	+33%	+$263K	0.61%	28
2020 Q4	$570K	Hold	30,000	–	–	0.33%	38
2020 Q3	$378K	Hold	30,000	–	–	0.25%	38
2020 Q2	$363K	Hold	30,000	–	–	0.22%	43
2020 Q1	$230K	Hold	30,000	–	–	0.2%	40
2019 Q4	$534K	Hold	30,000	–	–	0.39%	34
2019 Q3	$348K	Buy	+30,000	New	+$485K	0.23%	35

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Birchview Capital's KALV Position: Q1 2026 in Review

Birchview Capital held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 57,000 shares worth $1.15M. The position accounts for 0.65% of the portfolio, ranked #38.

Birchview Capital first reported a position in KALV in Q3 2019 and has held it in 27 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Birchview Capital held 57,000 shares of KalVista Pharmaceuticals worth $1.15M as of Q1 2026.
Birchview Capital left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up 0.65% of Birchview Capital's portfolio in Q1 2026, its #38 holding.
Birchview Capital first reported a position in KalVista Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.